The US Food and Drug Administration has granted a Breakthrough Therapy Designation to cobimetinib in the treatment of patients with histiocytic neoplasms (Erdheim-Chester Disease, Rosai-Dorfman, Langerhans Histiocytosis), who do not bear the BRAF V600 mutation. This...
De ECD Global Alliance kent een onderzoekssubsidie voor de ziekte van Erdheim-Chester toe aan het MSKCC om de celpopulatie die de ziekte veroorzaakt bij ECD in kaart te brengen en genetische veranderingen te vergelijken.
The ECD Global Alliance welcomes Duke Cancer Institute in Durham, NC into the referral care center network that serves ECD patients worldwide. Richard F. Riedel, MD will be leading the institute’s team at the Emerging Referral Care Center.
The ECD Global Alliance announces the launch of the Registry for Patients with Erdheim-Chester Disease led by Memorial Sloan Kettering Cancer Center (MSK), in New York, NY. The next step in building the registry database includes recruiting patients with ECD to...
Medical residents and physicians at Houston Methodist Hospital in Houston, TX learned about Erdheim-Chester disease from ECD Care Center lead, Mark Heaney, MD, PhD from Columbia University Medical Center. Also in attendance was ECDGA President, Kathy Brewer.
